Abexxa Biologics

Abexxa Biologics Focuses on Developing Novel Antibody Therapies for Cancer Treatment, Aiming to Revolutionize Cancer Care by Providing Highly Effective Targeted Therapies. The Foundation of the Company’s Technology is Based on Over 25 Years of Research and Development Experience in Novel Immunotherapies. Abexxa's Platform Can Generate Highly Specific Human Antibodies Against These Targets. The Company Has Developed Specific Expertise in Targeting the Non-Classical MHC Class I Molecule HLA-E, Which Has the Potential to Address a Broader Range of Cancer Antigens. Specifically, Abexxa Has Developed a Potential “First-in-Class” Antibody Similar to T Cell Receptors (TCR) That, by Binding to HLA-E, Can Block Its Interaction with the Inhibitory Immune Checkpoint Receptor NKG2A Expressed on Natural Killer Cells and T Cells, Thereby Activating Natural Killer Cells and Effector T Cells.